These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients. Eisenga MF; Zelle DM; Sloan JH; Gaillard CAJM; Bakker SJL; Dullaart RPF Diabetes Care; 2017 Jul; 40(7):894-901. PubMed ID: 28461454 [TBL] [Abstract][Full Text] [Related]
4. Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels. Cho Y; Lee MJ; Choe EY; Jung CH; Joo DJ; Kim MS; Cha BS; Park JY; Kang ES Liver Transpl; 2014 May; 20(5):557-63. PubMed ID: 24477986 [TBL] [Abstract][Full Text] [Related]
5. Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies. Szili-Torok T; Sokooti S; Osté MCJ; Gomes-Neto AW; Dullaart RPF; Bakker SJL; Tietge UJF Cardiovasc Diabetol; 2022 Mar; 21(1):41. PubMed ID: 35296331 [TBL] [Abstract][Full Text] [Related]
13. Risk factors and long-term consequences of new-onset diabetes after renal transplantation. Tomkins M; Tudor RM; Cronin K; O'Kelly P; Williams Y; Little D; de Freitas DG; Denton M; O'Seaghdha C; Conlon P; Smith D Ir J Med Sci; 2020 May; 189(2):497-503. PubMed ID: 31631244 [TBL] [Abstract][Full Text] [Related]
14. Hypomagnesemia and increased risk of new-onset diabetes mellitus after transplantation in pediatric renal transplant recipients. Hayes W; Boyle S; Carroll A; Bockenhauer D; Marks SD Pediatr Nephrol; 2017 May; 32(5):879-884. PubMed ID: 28039534 [TBL] [Abstract][Full Text] [Related]
15. Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients. Bae S; Ahn JB; Joseph C; Whisler R; Schnitzler MA; Lentine KL; Kadosh BS; Segev DL; McAdams-DeMarco MA Clin J Am Soc Nephrol; 2023 May; 18(5):626-633. PubMed ID: 36800538 [TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for development of new-onset diabetes after kidney transplantation. Bee YM; Tan HC; Tay TL; Kee TY; Goh SY; Kek PC Ann Acad Med Singap; 2011 Apr; 40(4):160-7. PubMed ID: 21678001 [TBL] [Abstract][Full Text] [Related]
17. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372 [TBL] [Abstract][Full Text] [Related]
19. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation. Liang J; Lv C; Chen M; Xu M; Zhao C; Yang Y; Wang J; Zhu D; Gao J; Rong R; Zhu T; Yu M J Diabetes; 2019 May; 11(5):370-378. PubMed ID: 30203544 [TBL] [Abstract][Full Text] [Related]
20. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Elens L; Sombogaard F; Hesselink DA; van Schaik RH; van Gelder T Pharmacogenet Genomics; 2013 Dec; 23(12):649-57. PubMed ID: 24113216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]